Prostate Cancer 2000: Projections for the Future
The detection and management of prostate cancer have improved considerably in the past decade and will be even more sharply defined in the future. Radiolabelled monoclonal antibodies are now available to detect occult soft tissue lesions of prostate cancer clinically by SPEC scanning. Lesions in lymph nodes and bone marrow are now visualised months before conventional techniques confirm this opportunity. As a result, the staging and earlier treatment of regionalised disease is possible.